Doença de Crohn: aspectos integrativos do diagnóstico ao tratamento

Fernando Tonholi  Dal Lin; Edson José Mazarroto; Paulo Cézar Gregório

doi:10.33448/rsd-v12i2.40368

Authors

Fernando Tonholi Dal Lin Universidade Federal do Paraná https://orcid.org/0000-0003-0461-2744
Edson José Mazarroto Centro Universitário do Paraná https://orcid.org/0000-0003-4893-266X
Paulo Cézar Gregório Universidade Federal do Paraná; Centro Universitário do Paraná https://orcid.org/0000-0002-8954-2855

DOI:

https://doi.org/10.33448/rsd-v12i2.40368

Keywords:

Crohn disease; Chronic intestinal inflammation; Symptoms; Diagnosis; Treatment.

Abstract

Objective: To identify current aspects throughout the course of Crohn's disease, from diagnosis, pharmacological and surgical treatments and nutritional recommendations. Method: This study is an integrative literature review based on the search for papers in databases, Pub Med, Lilacs, Scielo, Periodicals and websites, with the following descriptors in “Crohn's disease”, “Crohn's disease symptons”, “Crohn's Disease treatment”, “Inflammatory Bowel Diseases”, “Physiopathology of Inflammation”, using original research articles and reviews from 1990 to 2022. This bibliographic survey was carried out in the period of 03/01/2022 to 10/20/2022. Results: 1850 articles were found and, after using the inclusion criteria, 84 studies were selected. Discussion: Currently, the entire course of Crohn's disease is very complete, from diagnosis to treatment, which may involve biological drugs, in addition to the need for an adequate diet in order to avoid malnutrition in the patient. Conclusion: Considering all the complexity encompassed in Crohn's disease, the performance of a multidisciplinary team in the conduct of the patient's treatment is essential, which can contribute immensely to the patient's quality of life and adherence to treatment.

References

Abrahão, L. J., Jr., Abrahão, L.J., Vargas, C., Chagas, V., & Fogaça, H. (2001) Doença de Crohn gastroduodenal - relato de quatro casos e revisão da literatura. Arquivos de Gastroenterologia, 38(1), 57-62.

Ben‐Horin, & S., Chowers, Y. (2011). Loss of response to anti‐TNF trataents in Crohn’s disease. Alimentary pharmacology & therapeutics, 33(9), 987-995.

Benitez, S., Oliveira, R. M., Filho, & Molinari, H. (2004). Infliximabe. Vade-Mécum de substâncias de uso terapêutico (10a. ed., seção II, p.122). São Paulo, SP: Soriak.

Brant, S. R. (2011). Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflammatory bowel diseases, 17(1), 1-5.

Burgos, M. G. P. A., Salviano, F. N., Belo, G. M. S., & Bion, F. M. (2008). Doenças inflamatórias intestinais: o que há de novo em terapia nutricional? Revista Brasileira de Nutrição Clínica, 23(3), 184-189.

Cardoso, H., Magro, F., Azevedo, F., Queiroz, A., Nunes, A. C. R., Machado, A. S., & Veloso, F. T. (2006). Infliximab na doença de Crohn: estudo de 800 infusões em 136 doentes. Jornal Português de Gastrenterologia, 13, 214-219.

Cherry, L. N., Yunker, N. S., Lambert, E. R., Vaughan, D., & Lowe, D. K. (2015). Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease. Therapeutic advances in chronic disease, 6(5), 224-233.

Colombel, J. F., Sandborn, w. J., Reinisch, W., Mantzaris, G. J., Kornbluth, a., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., Tang, K. L., Woude, C. J. V. D., & Rutgeerts, P. (2010). Infliximab, azathioprine, or combination therapy for Crohn's disease. New England journal of medicine, 362 (15), 1383-1395.

Colombel, J. F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vanásek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hébuterne, X., Travis, s., Danese, S., Reinisch, W., Sandborn, W. J., Rutgeerts, P., Hommes, D., Schreiber, S., Neimark, E., Huang, B., Zhou, Q., Mendez, P., Petersson, J., Wallace, K., Robinson, A. M., Thakkar, R. B., & D’Haens, G. (2017). Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet, 390(10114), 2779-2789.

Correia, A. R. G. C. (2010). Doença de Crohn. Caso Clínico. (Dissertação de Mestrado). Universidade do Porto. Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal.

Cotran, R. S., Kumar, V., & Collins, T. (2000). Doença inflamatória intestinal. In Dayal, Y. & DeLellis, R. A. (ed.), Patologia estrutural e funcional (6a. ed., Cap. 18, pp. 732-734). Rio de Janeiro, RJ: Guanabara Koogan.

Cushing, K. & Higgins, P. D. R. (2021). Management of Crohn disease: a review. Jama Network, 325(1), 69-80.

Dharmasiri, S., Garrido-Martin, E. M., Harris, R. J., Bateman, A. C., Collins, J. E., Cummings, J. R. F., & Sanchez-Elsner, T. (2021). Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. Inflammatory Bowel Diseases, 27(10), 1641–1652.

Elia, P. P., Fogaça, H. S., Barros, R. G. G. R., Zaltman, C., & Elia, C. S. C. (2007). Análise descritiva dos perfis social, clínico, laboratorial e antropométrico de pacientes com doenças inflamatórias intestinais, internados no Hospital Universitário Clementino Fraga Filho. Arquivos de Gastroenterologia, 44(4), 332-339.

Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017). ACG clinical guideline: preventive care in inflammatory bowel disease. American Journal of Gastroenterology, 112(2), 241-258.

Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L., Miao, Y., Adedokun, O. J., sands, B. E., Hanauer, S. B., Vermeire, S., Targan, S., ghosh, S., Villiers, W. J., Colombel, J. F., Tulassay, Z., Seidler, U., Salzberg, B. A., Desreumaux, P., Lee, S. D., Loftus, E. V., Jr., Dieleman, L. A., Katz, S., & Rutgeerts, P. (2016). Ustekinumab as induction and maintenance therapy for Crohn’s disease. The New England journal of medicine, 375(20), 1946-1960.

Fisher, R. L. (1999). Wasting in chronic gastrointestinal diseases. The Journal of Nutrition, 129(1), 252-255.

Gisbert, J. P., Marín, A. C., & Chaparro, M. (2016). The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology, 111(5), 632-647.

Giuffrida, P., Caprioli, F., Facciotti, F., & Sabatino, A. D. (2019). The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmunity reviews, 18(5), 549-555.

Goldman, L. & Schafer, A. L. (2001). Tratado de Medicina Interna. (21a. ed). Rio de Janeiro, RJ: Guanabara Koogan.

Goodman, S. L., & Picard, M. (2012). Integrins as therapeutic targets. Trends in Pharmacological Sciences, 33(7), 405–412.

Govani, S. M., Noureldin, M., Higgins, P. D. R., Heisler, M., Saini, S. D., Stidham, R. W., Waljee, J. F., & Waljee, A. K. (2018). Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases. American journal of gastroenterology, 113(2), 276-282.

Greuter, T., & Vavricka, S. R. (2019). Extraintestinal manifestations in inflammatory bowel disease–epidemiology, genetics, and pathogenesis. Expert Review of Gastroenterology and Hepatology, 13(4), 307–317.

Grevenitis, P., Thomas, A., & Lodhia, N. (2015). Medical Therapy for Inflammatory Bowel Disease. Surgical Clinics of North America, 95(6), 1159–1182.

Grinman, A. B. (2012). Manifestações extraintestinais das doenças inflamatórias intestinais. Revista Hospital Universitário Pedro Ernesto, 11(4), 22-26.

Habr-Gama, A., Cerski, C. T. S., Moreira, J. P. T., Caserta, N. M. G., Oliveira, O., Jr., & Araújo, S. E. A. (2008). Doença de Crohn intestinal: manejo. Revista da Associação Médica Brasileira, 57(1), 10-13.

Hanauer, S. B. (1997). Doença inflamatória intestinal. In Bennett, J. C., Plum, F. (Org.) Cecil - Tratado de medicina interna (20a. ed., pp. 782-791). Rio de Janeiro-RJ: Guanabara Koogan.

Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Acosta, M. B., Boberg, K. M., Burisch, J., Vos, M. D., Vries, A. D., Dick, A. D., Juillerat, P., Karlsen, T. H., Koutroubakis, I., Lakatos, P. L., Orchard, T., Papay, P., Raine, T., Reinshagen, M., Thaci, D., Tilg, H., & Carbonnel, F. (2016). The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal of Crohn's and Colitis, 10(3), 239-254.

Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., & Kaplan, G. G. (2015). Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: A network meta-analysis. Gastroenterology, 148(2), 344-354.e5.

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., Mcgovern, D. P., Hui, K. Y., Lee, J. C., Schumm, L. P., Sharma, Y., Anderson, C. A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S. L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., Achkar, J. P., Ahmad, T., Amininejad, L., Ananthakrishnan, A. N., Andersen, V., Andrews, J. M., Baidoo, L., Balschun, T., Bampton, P. A., Bitton, A., Boucher, G., Brand, S., Büning, C., Cohain, A., Cichon, S., D’amato, M., Jong, D. D., Devaney, K. L., Dubinsky, M., Edwards, C., Ellinghaus, D., Ferguson, L. R., Franchimont, D., Fransen, K., Gearry,R., Georges, M., Gieger, C., Glas, J., Haritunians, T., Hart, A., Hawkey, C., Held, M., Hu, X., Karlsen, T. H., Kupcinskas, L., Kugathasan, S., Latiano, A., Laukens, D., Lawrance, I. C., Lees, C. W., Louis, E., Mahy, G., Mansfield, J., Morgan, A. R., Mowat, C., Newman, W., Palmieiri, O., Ponsioen, C. Y., Potocnik, U., Prescott, N. J., Regueiro, M., Rotter, J. I., Russell, R. K., Sanderson, J. D., Sans, M., Satsangi, J., Schreiber, S., Simms, L. A., Sventoraityte, J., Targan, S. R., Taylor, K. D., Tremelling, M., Verspaget, H. W., Vos, M. D., Wijmenga, C., Wilson, D. C., Winkelmann, J., Xavier, R. J., Zeissig, S., Zhang, B., Zhang, C. K., Zhao, H., Silverberg, M. S., Annese, V., Hakonarson, H., Brant, S. R., Radford-Smith, G., Mathew, C. G., Rioux, J. D., Schadt, E. E., Daly, M. J., Franke, A., Parkes, M., Vermeire, S., Barrett, J. C., & Cho, J. H. (2012). Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124.

Khanna, S., Shin, A., & Kelly, C. P. (2017). Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clinical Gastroenterology and Hepatology, 15(2), 166-174.

Khorshidi, M., Djafarian, K., Aghayei, E., & Shab-Bidar, S. (2020). A posteriori dietary patterns and risk of inflammatory bowel disease: a meta-analysis of observational studies. International Journal for Vitamin and Nutrition Research, 90(3-4), 376-384.

Kim, M. J., Kim, E., Kang, B., Lee, Y., Kang, E. S., & Choe, Y. H. (2021). Anti- Saccharomyces cerevisiae antibody in pediatric crohn’s disease patients without mucosal healing is a useful marker of mucosal damage. Gut and Liver, 15(5), 763.

Laass, M. W., Roggenbuck, D., & Conrad, K. (2014). Diagnosis and classification of Crohn’s disease. Autoimmunity Reviews, 13(4–5), 467–471.

Lanna, C. C. D., Ferrari, M. L. A., Carvalho, M. A. P., & Cunha, A. S. (2006). Manifestações articulares em pacientes com doença de Crohn e retocolite ulcerativa. Revista Brasileira de Reumatologia, 46(1), 45-51.

Lemaitre, M., Kirchgesner, J., Rudnichi, A., Carrat, F., Zureik, M., Carbonnel, F., & Dray-Spira, R. (2017). Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. Jama, 318(1)7, 1679-1686.

Lim, W.C., Wang, Y., Macdonald, J. K., & Hanauer, S. (2016). Aminosalicylates for induction of remission or response in Crohn's disease. The Cochrane Database of Systematic Reviews, 7(7), 1-109.

Lo, B., Vester-Andersen, M. K., Vind, I., Prosberg, M., Dubinsky, M., Siegel, C. A., Bendtsen, F., & Burisch, J. (2018). Changes in disease behaviour and location in patients with Crohn’s disease after seven years of follow-up: a Danish population-based inception cohort. Journal of Crohn's and Colitis, 12(3), 265-272.

Lundin, P. D. P., Edsbäcker, S., Bergstrand, M., Ejderhamn, J., Linander, H., Högberg, L., Person, T., Escher, J. C., & Lindquist, B. (2003). Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Alimentary pharmacology & therapeutics, 17(1), 85-92.

Macaluso, F. S., Orlando, A., & Cottone, M. (2019). Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opinion on Biological Therapy, 19(2), 89-98.

Magalhães, A. F. N. (1993). Doença de Crohn. In Dani, R., Castro, L. P. (Org.), Gastroenterologia clínica. (Vol. 1, 3a.. ed., pp. 765-777) Rio de Janeiro-RJ: Guanabara Koogan.

Magro, D. O., Barreto, M. R. L., Cazzo, E., Camargo, M. G., Kotze, P. G., & Coy, C. S. R. (2018). Visceral fat is increased in patients with Crohn’s disease: a comparative analysis with healthy controls. Arquivos de Gastroenterologia, 55(2), 142-147.

Moller, F. T., Andersen, V., Wohlfahrt, J., & Jess, T. (2015). Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. The American Journal of Gastroenterology, 110(4), 564–571.

Morhardt, T. L., Hayashi, A., Ochi, T., Quirós, M., Kitamoto, S., Nagao-Kitamoto, H., Kuffa, P., Atarashi, K., Honda, K., Kao, J. Y., Nusrat, A., & Kamada, N. (2019). IL-10 produced by macrophages regulates epithelial integrity in the small intestine. Scientific reports, 9(1), 1-10.

Mukherjee, S., Huda, S., & Babu, S. P. S. (2019). Toll‐like receptor polymorphism in host immune response to infectious diseases: A review. Scandinavian journal of immunology, 90(1), 1-18.

Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., Sung, J. J. Y., & Kaplan, G. G. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet, 390(10114), 2769-2778.

Oliveira, L. C. (2015). Doença de Crohn: etiopatogenia e tratamentos (Monografia). Faculdade de Educação e Meio Ambiente-FAEMA, Ariquemes, RO.

Oliveira, A. R., Oliveira, A. R., Maia, L. M. O., Barbalho, A. P., Brandão, L. B., & Passos, M. A. T. (2019). A importância da colonoscopia nas doenças inflamatórias intestinais. Revista de Saúde, 10(1), 08-12.

Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606-1619.

Panaccione, R., Colombel, J. F., Sandborn, W. J., D’Haens, G., Zhou, Q., Pollack, P. F., Thakkar, R. B., & Robinson, A. M. (2013). Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: Data from CHARM and ADHERE. Alimentary Pharmacology and Therapeutics, 38(10), 1236–1247.

Panés, J., López-Sanromàn, A., Bermejo, F., García-Sánchez, V., Esteve, M., Torres, Y., Domènech, E., Piqueras, M., Gomez-García, M., Gutiérrez, A., Taxonera, C., & Sans, M. (2013). Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology, 145(4), 766-774.

Park, S. C. & Jeen, Y. T. (2019). Genetic studies of inflammatory bowel disease-focusing on asian patients. Cells, 8(5), 1-22.

Pizarro, G., Quera, R., & Figueroa, C. (2017). Prognostic factors of ulcerative colitis at the moment of diagnosis. Revista medica de Chile, 145(10), 1319-1329.

Praag, E. M. M-V., Buskens, C. J., Hompes, R., & Bemelman, W. A. (2021). Surgical management of Crohn’s disease: a state of the art review. International Journal of Colorectal Disease, 36(6), 1133–1145.

Regueiro, M., Feagan, B. G., Zou, B., Johanns, J., Blank, M. A., Chevrier, M., Plevy, S., Popp, J., Cornillie, F. J., Lukas, M., Danese, S., Gionchetti, P., Hanauer, S. B., Reinisch, W., Sandborn, W. J., Sorrentino, D., Rutgeerts, P. (2016). Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease after Ileocolonic Resection. Gastroenterology, 150(7), 1568–1578.

Rodriguez-Palacios, A., Harding, A., Menghini, P., Himmelman, C., Retuerto, M., Nickerson, K. P., Lam, M., Croniger, C. M., McLean, M. H., Durum, S. K., Pizarro, T. T., Ghannoum, M. A., Ilic, S., McDonald, C., & Cominelli, F. (2018). The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn’s Disease-Like Ileitis. Inflammatory Bowel Diseases, 24(5), 1005–1020.

Rosa, B., Moreira, M. J., Rebelo, A., & Cotter, J. (2011). Enteroscopia por cápsula na suspeita de doença de Crohn: há lugar para o Score de Lewis na prática clínica? Jornal Português de Gastrenterologia, 10, 46-47.

Santos, J. C. M., Jr. (1999). Doença de Crohn: Aspectos clínicos e diagnósticos. Revista Brasileira de Colo-Proctologia, 19(4), 276-285.

Sarlo, R. S., Barreto, C. R., & Domingues, T. A. M. (2008). Compreendendo a vivência do paciente portador de doença de Crohn. Acta Paulista de Enfermagem, 21(4), 629-635.

Sganzerla, V. (2007). A revolução dos biológicos: opções de medicamentos contra Crohn e Colite ulcerativa chegam ao mercado (Ano VII, n. 30, p. 26). São Paulo-SP: Revista da Associação Brasileira de Colite Ulcerativa e Doença de Crohn – ABCD.

Silva, A. F., Schieferdecker, M. E. M., & Amarante, H. M. B. S. (2011). Ingestão alimentar em pacientes com doença inflamatória intestinal. Arquivos Brasileiros de Cirurgia Digestiva, 24(3), 204–209.

Souza, M. M., Belasco, A. G. S., & Aguilar-Nascimento, J. E. (2008). Perfil Epidemiológico dos Pacientes Portadores de Doença Inflamatória Intestinal do Estado de Mato Grosso. Revista Brasileira de Colo-Proctologia, 28(3), 324-328.

Souza, M. H. L. P., Troncon, L. E. A., Rodrigues, C. M., Viana, C. F. G., Onofre, P. H. C., Monteiro, R. A., Passos, A. D. C., Martinelli, A. L. C., & Meneghelli, U. G. (2002). Evolução da ocorrência (1980-1999) da doença de Crohn e da retocolite ulcerativa idiopática e análise das suas características clínicas em um hospital universitário do Sudeste do Brasil. Arquivos de Gastroenterologia, 39(2), 98-105.

Stevens, A. & Lowe, J. (2002). Patologia (2a. ed.) São Paulo-SP: Manole.

Tai, F. W. D. & Mcalindon, M. E. (2021). Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clinical Medicine, 21(2), 131-134.

Townsend, C. M., Parker, C. E., Macdonald, J. K., Nguyen, T. N., Jairath, V., Feagan, B. G., & Khanna, R. (2019). Antibiotics for induction and maintenance of remission in Crohn's disease. The Cochrane Database of Systematic Reviews, 2(2), 1-85.

Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology, 3(2), 133-146.

Uematsu, S., Fujimoto, K., Jang, M. H., Yang, B. G., Jung, Y. J., Nishiyama, M., Sato, S., Tsujimura, T., Yamamoto, M., Yokota, Y., Kiyono, H., Miyasaka, M., Ishii, K. J., & Akira, S. (2008). Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nature immunology, 9(7), 769-776.

Yamane, I. S., Reis, R. S., & Moraes, H. V., Jr. (2007). Oclusão venosa central de retina na remissão de doença de Crohn: relato de caso. Arquivos Brasileiros de Oftalmologia, 70(6), 1034-1036.

Zhou, M., He, J., Shen, Y., Zhang, C., Wang, J., & Chen, Y. (2017). New frontiers in genetics, gut microbiota, and immunity: a rosetta stone for the pathogenesis of inflammatory bowel disease. BioMed Research International, 2017, 1-17.

Crohn's disease: integrative aspects from diagnosis to treatment

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

JOURNAL METRICS

Language

Make a Submission